Since the initiation of our Phase I trial in Europe and Israel, we are advancing our novel NG CELL™ platform to develop, manufacture, and deliver the next generation of cell therapies for neurodegenerative diseases.
Our foundational science harnesses the NG platform’s ability to enhance stem cells by maximizing their remyelination factors secretions, neuronal protection and regenerative capabilities.
We are excited about delivering on the promise of remyelinating and regenerative cellular therapies, shaping the future of cellular medicine, and delivering new therapies to many unmet needs in the neurodegenerative diseases market.
NeuroGenesis will initiate a multi-center Phase IIb clinical trial (Secondary Progressive Multiple Sclerosis) in 2023 as well as a Phase IIb in ALS (Lou Gehrig’s disease).
An accomplished senior executive with over 16 years of CEO experience in public and private companies in Tel Aviv, New York and Silicon Valley. Established and directly managed global high growth sales, business development organizations in North America, Europe and Asia (direct Sales, Inside Sales, One Tier, Two-Tiered Distribution, OEM, IP Licensing etc.).
CEO of AppDome, a recognized market leader in mobile integration as a service (security, connectivity, mobility). Recognized by CIO magazine as one of 2015’s Top 10 Mobility CEOs as well as a 2015 Top Mobile Innovator by the Channel Company. President and CEO of INKSURE Technologies, the industry leader in cloud-based mobile product authentication. Winner of the 2011 Prestigious ID People Americas Award, the Oscars of the ID Industry, for his contribution to the high-security authentication market. Proven track record in the software, hardware industry of increasing top and bottom-line results, previously heading SanDisk Enterprise (NASDAQ: SNDK) in North America and M-System (NASDAQ: FLSH) Enterprise business. In 2000, founded and served as CEO of Kavado Inc. (acquired by Protegrity Inc.), a global web security solutions provider.
Tal holds an MBA from Columbia Business School in New York and a BA with honors in Economics, Business Administration from the Hebrew University in Jerusalem.
Dr. Karussis is considered one the world experts in clinical applications of Stem Cells in Neurological diseases, he is the director of MS Center and department of Neuroimmunology, Cell Therapies at Hadassah Medical Center, Jerusalem (since 2007). Dr. Karussis servers on many editorial boards including the International Multiple Sclerosis, Journal of Neurological Sciences, World Journal of Neurology and others. Dr. Karussis has participated in numerous scientific committees at ECTRIMS, EFNS, ISNI and the European School of Neuroimmunology. Dr. Karussis also serves as the president of the Israeli Neuroimmunology Society (since 2010) and has published over 120 peer-reviewed scientific papers mainly in the field of Stem Cells and Neuroimmunology.
Dr. Kassis is one of the world’s experts in Regenerative Medicine and stem-cells based technologies, and production of clinical-grade stem cells for treating multiple sclerosis andamyotrophic lateral sclerosis patients. Dr. Kassis has over 20 years of experience in developing innovative cellular therapies from bench to patient bedside. Dr. Kassis serves as a Senior Scientist at the Department of Neurology, Hadassah Medical Center. Dr. Kassis has published over 30 publications in prestigious peer reviewed publications.
Dr. Netzer served for over 15 years in cell therapy companies in Israel and in the US as a member of the management team. He is an expert in Stem Cell R&D and operations and in establishing a global strategy for product development, manufacturing, and supply chain, with a clear focus on market viability. Before joining NeuroGenesis, Dr. Netzer served as the VP CMC and Operations at Cell
Cure Neurosciences, acquired by Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), where he led the development of a novel ‘Thaw- and-Inject’ cell product and the building of Lineage’s state of the art GMP manufacturing facility. Previously, Dr. Netzer was the Research Manager at Pluristem Therapeutics Inc. (NASDAQ: PSTI), where he led the preclinical trials and the finding of the first cell therapy product for treating radiation syndrome following nuclear disasters. Dr. Netzer was a Post-Doctoral fellow in cell biology and viral immunology at the NIAID, NIH and holds a PhD in Biotechnology and immunology from the Technion in Israel.
Dr. Snyder has worked on the executive management teams of international pharmaceutical and biotechnology companies in the US and in Israel. For the past 10 years, David was the VP, Clinical Development, Regulatory Affairs at Gamida Cell (NASDAQ: GMDA), a phase 3 cell therapy company. David is highly experienced in the design and management of clinical strategies and protocols as well as the supervision of sponsor interactions with the regulatory agencies in these areas. His focus for nearly the last fifteen years has been advising and directing high-level communications with opinion leaders, consultants and regulatory agencies in the field of cellular therapies. David earned a Ph.D. in medical biochemistry from the Hebrew University.